Results 71 to 80 of about 182,500 (270)

Self‐Assembling Peptide‐Adjuvant Conjugate (SaPAC) Platform for Precision Cancer Immunotherapy

open access: yesAdvanced Science, EarlyView.
A self‐assembling peptide–adjuvant conjugate links neoantigens to TLR7 agonism, forming cationic nanoparticles that enhance lymph‐node retention, dendritic‐cell activation, and antitumor T‐cell immunity. This chemically defined platform shows how synchronized antigen and innate stimulation can be adapted across melanoma, bladder cancer, and triple ...
Yang‐Fan Wu   +15 more
wiley   +1 more source

Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non‐small cell lung cancer

open access: yesCPT: Pharmacometrics & Systems Pharmacology, 2023
Enrolling patients in immunotherapy clinical trials is becoming increasingly competitive. Virtual clinical trials can help investigators answer key questions despite this.
Timothy Qi, Yanguang Cao
doaj   +1 more source

Tumor Lysis Syndrome Due to Pembrolizumab Use in Metastatic Nasopharyngeal Carcinoma

open access: yes
In this case, we report tumor lysis syndrome (TLS) in a patient with metastatic nasopharyngeal carcinoma treated with pembrolizumab. There are only a few studies reporting the development of TLS associated with pembrolizumab, but this is the first report
ÇAĞLAR, ALPEREN AKANSEL   +13 more
core   +1 more source

Spatial Transcriptomics Reveals a T Cell‐Mediated Microglial Activation Axis of Immune Checkpoint Inhibition‐Related Adverse Events in the Brain

open access: yesAdvanced Science, EarlyView.
Immune checkpoint inhibition (ICI) reshapes the hippocampal neuroimmune niche. Spatial transcriptomic profiling and human brain histological analyses identify neuroinflammation and altered neuronal and glial programs. Notably, T cell depletion prevents ICI‐driven microglial activation, establishing the T cell–microglia crosstalk axis as a driving ...
Devyani Swami   +7 more
wiley   +1 more source

Pembrolizumab-induced necrotizing diaphragmatic myositis

open access: yes
Pembrolizumab, an anti-PD1 antibody, is increasingly used for the treatment of non-small cell lung cancer. We report a severe and poorly described adverse effect of this therapy: necrotizing myopathy with diaphragmatic and myocardial involvement.
Noemí Vidal   +3 more
core   +1 more source

ERα–PADI4–CXCL8 Axis Drives MDSC‐Mediated Immune Evasion in Anaplastic Thyroid Carcinoma

open access: yesAdvanced Science, EarlyView.
MAPK‐driven ligand‐independent ERα activation drives PADI4 transcription and translation. This enzyme then modifies CXCL8 chemokines through citrullination, generating a potent chemoattractant gradient specifically for myeloid‐derived suppressor cells.
Dongdong Zhang   +5 more
wiley   +1 more source

Immunogenicity of pembrolizumab in patients with advanced tumors

open access: yesJournal for ImmunoTherapy of Cancer, 2019
Background Pembrolizumab is a potent, humanized, monoclonal anti–programmed death 1 antibody that has demonstrated effective antitumor activity and acceptable safety in multiple tumor types. Therapeutic biologics can result in the development of antidrug
Marianne J. H. van Vugt   +14 more
doaj   +1 more source

SPRED2 Negatively Regulates CD8+ T Cell‐Mediated Antitumor Immunity in Breast Cancer

open access: yesAdvanced Science, EarlyView.
Sprouty‑related EVH1 domain containing 2 (SPRED2) restrains Ras/Raf/ERK signaling in CD8+ T cells. Host SPRED2 deficiency enhances T‐cell survival, cytotoxicity, and memory‐like phenotypes, reducing primary tumor growth and endpoint lung metastatic burden in breast cancer models.
Miao Tian   +8 more
wiley   +1 more source

CXCL3 Antagonism Reverses Systemic Antitumor Immune Memory Impairment Associated With High Tumor Burden and Sensitizes Anti‐PD‐1 Therapy

open access: yesAdvanced Science, EarlyView.
This study reveals that large tumors secrete more chemokine CXCL3, which recruits immunosuppressive neutrophils to the periphery, thereby impairing the activation and memory of systemic tumor‑reactive CD8+ T cells. CXCL3 antagonism restores systemic immune memory and enhances the antitumor efficacy of anti‑PD‑1 therapy, offering a potential strategy to
Ji Wang   +15 more
wiley   +1 more source

Patient‐Derived Glioblastoma Organoids for AI‐Guided Prediction of Therapeutic Response

open access: yesAdvanced Science, EarlyView.
Patient‐derived glioblastoma organoids provide clinically relevant models that preserve tumor heterogeneity and enable integrated AI‐driven analysis of imaging, molecular, and treatment‐response data. Their convergence with advanced analytics supports predictive, personalized therapeutic strategies and may accelerate translation from patient‐specific ...
Sandbhor Puja   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy